• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck shares slip after hours as Alzheimer's study halted

    Merck shares slip after hours as Alzheimer's study halted

  2. UPDATE: Shares of manufacturers whose CEOs met Trump today are slumping, led by U.S. Steel

    UPDATE: Shares of manufacturers whose CEOs met Trump today are slumping, led by U.S. Steel

  3. UPDATE: Shares of manufacturers whose CEOs met Trump today are slumping, led by U.S. Steel

    UPDATE: Shares of manufacturers whose CEOs met Trump today are slumping, led by U.S. Steel

  4. Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results

    Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results

  5. FDA Accepts Two sBLAs for Merck ’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment ...

    FDA Accepts Two sBLAs for Merck ’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings

  6. Merck matches profit expectations but sales come up a bit short

    Merck matches profit expectations but sales come up a bit short

  7. Merck earnings stock gains give way after Keytruda revenue turns out to be a miss

    Merck earnings stock gains give way after Keytruda revenue turns out to be a miss

  8. Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Update

    Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Update

  9. New Pressure on Drug Giant -- WSJ

    New Pressure on Drug Giant -- WSJ

  10. Women's Health Medical Devices Pipeline Assessment 2016 - Research and Markets

    Women's Health Medical Devices Pipeline Assessment 2016 - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.